盐酸安罗替尼对晚期肺鳞癌的临床疗效研究

Clinical Efficacy of Arotinib Hydrochloride for Advanced Lung Squamous Cell Carcinoma

目的探讨盐酸安罗替尼维持治疗一线化疗后晚期肺鳞癌的疗效及安全性。方法收集40例晚期肺鳞癌患者,已完成4~6个疗程标准化疗,应用随机抽签的方式将患者分为试验组及对照组,每一组20例患者,对照组给予最佳支持治疗,实验组给予安罗替尼维持治疗,比较两组PFS、血清VEGFR水平、KPS评分及安全性。结果试验组和对照组的中位PFS分别为8.7个月和4.5个月(P<0.05)。维持治疗开始前试验组与对照组患者血清中血管内皮生长因子(VEGF)水平比较差异无统计学意义(P>0.05),治疗后试验组患者血清中VEGF-2水平明显低于对照组(260.44±17.32 vs 320.15±19.04)pg/ml,(P<0.05)。盐酸安罗替尼治疗后患者KPS评分基本维持在1分。患者不良反应轻,主要为高血压、手足综合征及黏膜溃疡,经治疗后均能缓解。结论盐酸安罗替尼维持治疗一线化疗后病情稳定的晚期肺鳞癌患者,可提高PFS,维持较好的KPS评分,安全性好。

Objective To explore the efficacy and safety of maintenance therapy with arotinib hydrochloride for advanced lung squamous cell carcinoma after first-line chemotherapy.Methods 40 patients with advanced lung squamous cell carcinoma who had completed 4~6 courses of standard chemotherapy were collected and randomly divided into the experimental group and the control group.Each group had 20 patients,and the control group received the best supportive treatment.The experimental group received maintenance treatment with arotinib.PFS,serum VEGFR levels,KPS scores,and safety were compared between the 2 groups.Results The median PFS of the experimental group and the control group were 8.7 months(95%CI:6.7~11.0)and 4.5 months(95%CI:3.7~6.0),respectively(P<0.05).Before the start of maintenance treatment,there was no statistically significant difference in the serum levels of vascular endothelial growth factor(VEGF)between the experimental group and the control group(P>0.05).After treatment,the serum VEGF-2 levels in the experimental group were significantly lower than those in the control group(260.44±17.32 vs 320.15±19.04)pg/ml,(P<0.05).After treatment with arotinib hydrochloride,the patient's KPS score remained basically at 1 point.The patient has mild adverse reactions,mainly hypertension,hand foot syndrome,and mucosal ulcers,which can be alleviated after treatment.Conclusion Anlotinib hydrochloride maintenance therapy can improve PFS,maintain a good KPS score,and have good safety in patients with advanced lung squamous cell carcinoma who have stable conditions after first-line chemotherapy.